

**REMARKS**

This communication is responsive to the Office communication dated April 11, 2011. Claims 78 and 98–115 are pending in the application.

In the Office communication, the Examiner requested election of one species of therapeutic agent from claims 102 and 103 and one species of injection means from claims 109 to 111. In response, applicants elect a high-density lipoprotein cholesterol from the therapeutic agents of claims 102 and 103. All of the pending claims are readable on the elected species of therapeutic agent. Applicants also elect a bioreactor formation catheter (claim 110) from among the species of injection means recited in claims 109 to 111. All of the pending claims except claims 109 and 111 are readable on the elected species of injection means.

Applicants believe that this communication is fully responsive to the Office action. However, if the Examiner has any questions, or if a telephone interview would in any way advance prosecution of the application, please contact the undersigned attorney of record.

Respectfully submitted,

KOLISCH HARTWELL, P.C.

/ James R. Abney /

---

James R. Abney  
Registration No. 42,253  
Customer No. 23581  
520 S.W. Yamhill Street, Suite 200  
Portland, Oregon 97204  
Telephone: (503) 224-6655  
Facsimile: (503) 295-6679  
Attorney of Record